Voice Technology Company ArkX Laboratories Inks European Sales Agreement With Redtree Solutions
17.11.2020 09:00:00 EET | Business Wire | Press release
ArkX Laboratories, a leading provider of advanced far-field voice-capture technology, has appointed Redtree Solutions, the largest Pan-European electronic representative in the semiconductor industry, as the exclusive sales representative for its production-ready EveryWord™ voice solution in the Europe, Middle East and Africa (EMEA) marketplace.
This announcement coincides with growing demand from Fortune 1000 companies, OEMs, and start-ups in the region who want to bring their voice-enabled smart products and devices to market. The EveryWord™ portfolio offers a production-ready path that delivers an unmatched voice experience while mitigating risk, reducing development costs, and accelerating their time-to-market.
Featuring Cirrus Logic's SoundClear™ and FlexArray™ technologies, ArkX's advanced line of production-ready voice capture solutions outperform other existing solutions in far-field voice capture and deliver a far-superior voice experience to consumers. The products are Alexa-compatible and meet or exceed all requirements for the Amazon Voice Services (AVS) qualifications. In addition to Alexa, EveryWord™ is compatible with other platforms such as Google, Siri, Cortana, AliGenie, Baidu/Kitt.ai, Tencent, and Sensory. EveryWord™ voice solutions can be customized for a company's eco-system and applied to a wide range of products, including speakers, soundbars, televisions, appliances, voice controllers, and gadgets. For smart home applications, the modules can be installed in hubs, ceilings, and in-wall.
"The ArkX EveryWord portfolio solves the toughest problems facing innovative OEMs today, including capturing voice at a greater distance, around corners, in the presence of blaring TV, and other noisy and reverberative environments without having to lower playback volume," said ArkX CEO Eric Bauswell. "EveryWord truly outperforms the performance of standard far-field voice solutions by so large a margin that consumers will never want to go back to the 'old' technology."
Covering 19 countries with more than 500 active customers, Redtree will help accelerate ArkX Labs' market penetration in the region by generating greater awareness of the company's solutions and providing on-the-ground support to ArkX Labs' expanding customer base.
"We were impressed with the innovation and superior far-field performance of the EveryWord™ solutions. It's a huge leap forward and certainly the best far-field solutions ever seen on the marketplace over our 10+ years' experience in this segment," said Steve Judge, Redtree Solutions Managing Director. "The addition of ArkX's EveryWord™ voice solutions represent a strategic addition to our electronic component portfolio that will have appeal to many of our customers operating in the smart home, broadband telecom, consumer, robotic, automotive, and industrial marketplaces."
ArkX Executive Vice President Michael Lang added, "Redtree's experience, expertise, and support structure provides the perfect fit to help us expand our reach beyond existing North American and Asian markets."
The product line offers clear performance advantages for capturing voice commands from three times the standard distance, around corners, noisy and reflective environments, and without lowering playback volume. Additionally, EveryWord™ technology provides a unique ability to identify and to suppress speech from TV or other single-point noise sources.
EveryWord™ technology does not require source-ducking for reliable interaction, provides linear, circular, square, triangular, or 3D mic array geometries, and requires fewer microphones. The technology features ultra-low power battery operation for wake-on-word, and the flexibility for placement of microphones allows for in-wall, ceiling, or dashboard solutions. The 3D mic array versus other linear beam-forming approaches enables fewer blind spots and increased performance while incorporating fewer redundant microphone arrays for coverage.
About ArkX Laboratories
ArkX Laboratories, a joint venture between product development pioneer, Surfaceink, and consumer electronics manufacturer Ark Electronics USA brings an exceptional voice experience to the marketplace. Our next generation of advanced, high-performance far-field voice capture solutions, featuring Cirrus Logic and NXP technology, are Amazon pre-qualified and production-ready. ArkX provides Fortune 1000, OEMs, and start-ups who want their own branded, voice-enabled IoT products and smart devices with the ability to reduce their development time and costs and accelerate their time-to-market while mitigating the risk. For more information, please visit www.arkxlabs.com.
About Redtree Solutions
Redtree Solutions is the largest Pan-European Representative company in the region. More than 40 people provide service, speak local languages, and cover 19 countries with more than 500 active customers. Redtree invests in next-generation technologies for the benefit of its customers and is dedicated to their success. The Redtree application team is devoted to helping customers find the most optimized architecture for your Electronic systems, with the help of their partners' solutions and expertise. Redtree is headquartered near Oxford, UK. For more information, please visit www.redtree-solutions.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201116006041/en/
Contact information
Jean-Marie Houillon, +33 (0)1 30 47 25 33
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 11:22:00 EET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom